Total submissions: 14
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000163315 | SCV000213843 | benign | Hereditary cancer-predisposing syndrome | 2015-09-06 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001081765 | SCV000261941 | benign | Gastrointestinal stromal tumor; Paragangliomas 4; Pheochromocytoma | 2025-02-04 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000266464 | SCV000351429 | likely benign | Carney-Stratakis syndrome | 2019-04-21 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000323978 | SCV000351430 | likely benign | Hereditary pheochromocytoma-paraganglioma | 2019-04-21 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Gene |
RCV000713176 | SCV000730537 | likely benign | not provided | 2020-08-25 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 23512077, 25694510, 21979946, 25394176, 19802898, 18458953, 23072324, 20923864, 28873162, 30152102) |
Athena Diagnostics | RCV000713176 | SCV000843759 | benign | not provided | 2018-01-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000602372 | SCV001478595 | benign | not specified | 2021-01-17 | criteria provided, single submitter | clinical testing | Variant summary: SDHB c.158G>A (p.Gly53Glu) results in a non-conservative amino acid change located in the 2Fe-2S ferredoxin-type iron-sulfur binding domain (IPR010141) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00053 in 251378 control chromosomes in the gnomAD database, including 1 homozygote. The observed variant frequency is higher than the estimated maximal expected allele frequency for a pathogenic variant in SDHB causing Hereditary Paraganglioma-Pheochromocytoma Syndrome phenotype (2.2e-07), strongly suggesting that the variant is benign. Although, this variant has been reported in the literature (example, Fishbein_2013, Cox_2018), to our knowledge, no occurrence of c.158G>A in individuals affected with Hereditary Paraganglioma-Pheochromocytoma Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign (n=3)/likely benign (n=2). Based on the evidence outlined above, the variant was classified as benign. |
Sema4, |
RCV000163315 | SCV002527060 | benign | Hereditary cancer-predisposing syndrome | 2021-07-15 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000602372 | SCV002552241 | likely benign | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000713176 | SCV004220332 | benign | not provided | 2018-01-08 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV003514320 | SCV004362281 | benign | Paragangliomas 4 | 2022-09-20 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000713176 | SCV004700590 | benign | not provided | 2024-12-01 | criteria provided, single submitter | clinical testing | SDHB: BS1, BS2 |
Genome |
RCV000709876 | SCV000840213 | not provided | Gastrointestinal stromal tumor; Carney-Stratakis syndrome; Paragangliomas 4; Pheochromocytoma; Cowden syndrome 1 | no assertion provided | phenotyping only | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. | |
Prevention |
RCV004535070 | SCV004743598 | likely benign | SDHB-related disorder | 2020-07-13 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |